Bogdan Iulius Florea

Bogdan Iulius Florea

Auto-generated profile, based on publicly available information

Bogdan Iulius Florea

Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2300 RA Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2006 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PMPierre-Olivier Mari
Pierre-Olivier Mari
BFBogdan I. Florea
Bogdan I. Florea
SPStephan P. Persengiev
Stephan P. Persengiev
NVNicole S. Verkaik
Nicole S. Verkaik
HBHennie T. Brüggenwirth
Hennie T. Brüggenwirth
DGDik C. van Gent
Dik C. van Gent
DNA double-strand break (DSB) repair by nonhomologous end joining (NHEJ) requires the assembly of several proteins on DNA ends. Although biochemical studies have elucidated several aspects of the NHEJ reaction mechanism, much less is known about NHEJ in living cells, mainly because of the inability to visualize NHEJ repair proteins at DNA damage. Here we provide evidence that a pulsed near IR laser can produce DSBs without any visible alterations in the nucleus, and we show that NHEJ proteins accumulate in the irradiated areas. The levels of DSBs and Ku accumulation diminished in time, showing that this approach allows us to study DNA repair kinetics in vivo . Remarkably, the Ku heterodimers on DNA ends were in dynamic equilibrium with Ku70/80 in solution, showing that NHEJ complex assembly is reversible. Accumulation of XRCC4/ligase IV on DSBs depended on the presence of Ku70/80, but not DNA-PK CS . We detected a direct interaction between Ku70 and XRCC4 that could explain these requirements. Our results suggest that this assembly constitutes the core of the NHEJ reaction and that XRCC4 may serve as a flexible tether between Ku70/80 and ligase IV.

9 June 2017 in Science
Verified
Journal Article
Closed access
PDF file
AEAnnelot C. M. van Esbroeck
Annelot C. M. van Esbroeck
AJAntonius P. A. Janssen
Antonius P. A. Janssen
ACArmand B. Cognetta
Armand B. Cognetta
DODaisuke Ogasawara
Daisuke Ogasawara
GSGuy Shpak
Guy Shpak
MSMario van der Stelt
Mario van der Stelt
A clue to a drug's neurotoxicity?: The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered brain damage. As an initial step in investigating whether inhibition of off-target proteins by BIA 10-2474 might contribute to its clinical neurotoxicity, van Esbroeck et al. used activity-based proteomic assays to identify proteins targeted by the drug. Studying human cells and brain samples from subjects not associated with the trial, they found that BIA 10-2474 targeted several different lipases in addition to FAAH. It also substantially altered lipid metabolism in cultured neurons. Science , this issue p. 1084

1 April 2011 in Immunity
Verified
Journal Article
Closed access
JCJohn T. Chang
John T. Chang
MCMaria L. Ciocca
Maria L. Ciocca
IKIchiko Kinjyo
Ichiko Kinjyo
VPVikram R. Palanivel
Vikram R. Palanivel
CMCourtney E. McClurkin
Courtney E. McClurkin
SRSteven L. Reiner
Steven L. Reiner

1 November 2006 in Chemistry & Biology
Verified
Journal Article
Closed access
MVMartijn Verdoes
Martijn Verdoes
BFBogdan I. Florea
Bogdan I. Florea
VMVictoria Menendez-Benito
Victoria Menendez-Benito
CMChrista J. Maynard
Christa J. Maynard
MWMartin D. Witte
Martin D. Witte
HOHerman S. Overkleeft
Herman S. Overkleeft

1 September 2002 in AAPS PharmSci
Verified
Journal Article
Closed access
PDF file
BFBogdan I. Florea
Bogdan I. Florea
CMClare Meaney
Clare Meaney
HJHans E. Junginger
Hans E. Junginger
GBGerrit Borchard
Gerrit Borchard

27 April 2016 in Leukemia
Verified
Journal Article
Open access
GSG P Soriano
G P Soriano
LBL Besse
L Besse
NLN Li
N Li
MKM Kraus
M Kraus
ABA Besse
A Besse
CDChristoph Driessen
Christoph Driessen
Adaptive resistance of myeloma to proteasome inhibition represents a clinical challenge, whose biology is poorly understood. Proteasome mutations were implicated as underlying mechanism, while an alternative hypothesis based on low activation status of the unfolded protein response was recently suggested (IRE1/XBP1-low model). We generated bortezomib- and carfilzomib-adapted, highly resistant multiple myeloma cell clones (AMO-BTZ, AMO-CFZ), which we analyzed in a combined quantitative and functional proteomic approach. We demonstrate that proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition, irrespective of a proteasome mutation, and uniformly show an 'IRE1/XBP1-low' signature. Adaptation of myeloma cells to proteasome inhibitors involved quantitative changes in >600 protein species with similar patterns in AMO-BTZ and AMO-CFZ cells: proteins involved in metabolic regulation, redox homeostasis, and protein folding and destruction were upregulated, while apoptosis and transcription/translation were downregulated. The quantitatively most upregulated protein in AMO-CFZ cells was the multidrug resistance protein (MDR1) protein ABCB1, and carfilzomib resistance could be overcome by MDR1 inhibition. We propose a model where proteasome inhibitor-adapted myeloma cells tolerate subtotal proteasome inhibition owing to metabolic adaptations that favor the generation of reducing equivalents, such as NADPH, which is supported by oxidative glycolysis. Proteasome inhibitor resistance may thus be targeted by manipulating the energy and redox metabolism.